SCHEDULE: FMR LLC Discloses 9% Stake in Moonlake Immunotherapeutics

FMR LLC and Abigail P. Johnson have disclosed a 9.0% beneficial ownership stake in Moonlake Immunotherapeutics' Class A Common Stock as of June 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson reported beneficial ownership of 5,703,048.73 shares of Moonlake Immunotherapeutics' Class A Common Stock.
• This represents 9.0% of the outstanding Class A Common Stock.
• FMR LLC holds sole voting power over 5,700,976.70 shares and sole dispositive power over 5,703,048.73 shares.
• Abigail P. Johnson holds sole dispositive power over 5,703,048.73 shares.
• The filing is an Amendment No. 3 to Schedule 13G, indicating an update to a previously reported stake.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive stake by a major institutional investor, FMR LLC, which can be viewed positively as a vote of confidence. However, it's a routine ownership disclosure and doesn't contain operational or financial performance details of the issuer.

Positives

• A significant institutional investor, FMR LLC (Fidelity), maintains a substantial 9.0% stake, indicating continued confidence in Moonlake Immunotherapeutics.
• The filing explicitly states the shares are held in the ordinary course of business and not for influencing control, suggesting a passive, long-term investment perspective.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Moonlake Immunotherapeutics' future performance or strategic outlook.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects a significant passive investment by a major asset manager, FMR LLC, in a biotechnology company, Moonlake Immunotherapeutics. Such investments are common in the biotech sector, where institutional investors often take positions in companies with promising drug pipelines or technologies, reflecting confidence in long-term growth potential rather than short-term operational influence.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, which is a routine disclosure for institutional investors acquiring over 5% of a company's shares.
• The 9.0% stake is a substantial passive position, comparable to other large institutional holdings seen in emerging biotechnology companies where major funds like Fidelity (FMR LLC) seek exposure to innovative therapies.
• No specific comparable companies or projects are mentioned in the filing itself, as it focuses solely on ownership disclosure.

Stakeholder Impact

• Shareholders: May view the significant institutional ownership as a positive signal of investor confidence.
• Management: The passive nature of the investment (not seeking control) suggests no immediate pressure for strategic changes from this investor.

Next Steps

• The filing does not specify any future actions or milestones for Moonlake Immunotherapeutics or the reporting persons beyond the ongoing passive investment.

Key Dates

Recommendation

The filing is a routine disclosure of a significant passive ownership stake by FMR LLC (Fidelity) in Moonlake Immunotherapeutics. While the 9.0% stake by a major institutional investor is a positive signal of confidence, this filing does not provide new operational, financial, or strategic information about Moonlake Immunotherapeutics that would warrant a change in investment thesis. It primarily confirms continued institutional interest, suggesting a 'hold' recommendation for investors already in the stock, or a 'monitor' for those considering it, pending further fundamental updates from the company.

Keywords

Moonlake Immunotherapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Class A Common Stock, Biotechnology, Immunotherapy, SEC Filing